Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2023 0 · FY2024 90 — 2-yr total 90
Abulpharm LLC is a Tbilisi-based pharmaceutical distributor and wholesaler set up with Turkish investment (~USD 2m), operating a pharmaceutical warehouse in the Gldani industrial zone with regional export activity, particularly to Russia.
| Line item | 2023 | 2024 | CAGR |
|---|---|---|---|
| Net Cash from Operating Activities | 343 | 431 | +25.7% |
| Net Cash used in Investing Activities | 0 | 789 | |
| Free Cash Flow (OCF − Capex proxy) | 343 | 358 | nmf |
| Net Cash from Financing Activities | 51 | 90 | nmf |
| Net Change in Cash (before FX) | 394 | 448 | nmf |
| Effect of FX on Cash | 10 | 9,073 | nmf |
| Net Change in Cash (incl. FX) | 404 | 8,625 | +2034.9% |
| Cash at Beginning of Year | 0 | 404 | |
| Cash at End of Year | 404 | 9,029 | +2134.9% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →